{"id":"W4248269869","doi":"10.1016/s0140-6736(08)60726-6","title":"Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1350,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University; Probity Medical Research; Western University","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical endpoint; Dosing; Internal medicine; Intention-to-treat analysis; Randomized controlled trial; Adverse effect; Gastroenterology; Immunology; Tumor necrosis factor alpha; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002848021,0.001979423,0.004298964,0.0006058897,0.0006170648,0.001309669,0.0009547526,0.003268561,0.006720296],"category_scores_gemma":[0.002582941,0.001155125,0.002603848,0.0005697026,0.001483302,0.00154765,0.0004853471,0.003768216,0.001202306],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007435179,"about_ca_system_score_gemma":0.0007221423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001213889,"about_ca_topic_score_gemma":0.001549731,"domain_scores_codex":[0.9989116,0.000557485,0.00007404034,0.0002070286,0.00008495457,0.0001649353],"domain_scores_gemma":[0.998828,0.000392614,0.0002652979,0.0001070963,0.00007114133,0.0003359368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9866094,0.001966632,0.0003526994,0.0003980557,0.0006388912,0.00002247515,0.00002961428,0.0001109669,0.002159383,0.00002796104,0.0003497026,0.007334179],"study_design_scores_gemma":[0.9700419,0.02704469,0.001716352,0.00002057343,0.0005145452,0.00002040026,0.00001111304,0.00009789952,0.0002781667,0.00004187608,0.0002014204,0.00001106479],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9789058,0.01309827,0.0007861299,0.001080757,0.0006056228,0.001657721,0.001424381,0.0001766708,0.002264627],"genre_scores_gemma":[0.9860525,0.004972059,0.001154818,0.001447705,0.000701596,0.001431826,0.001300619,0.000045259,0.00289352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006720296,"threshold_uncertainty_score":0.02248168,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03514495136420409,"score_gpt":0.2649833830382751,"score_spread":0.229838431674071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}